Lysosomal storage disease (LTD) is caused by defect in lysosomal functions and degradation pathway. It is caused by progressive accumulation of metabolites. LTD is a rare inherited metabolic disorder.
This report contains market size and forecasts of Lysosomal Storage Disease Treatment in Global, including the following market information:
Global Lysosomal Storage Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Lysosomal Storage Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Enzyme Replacement Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Lysosomal Storage Disease Treatment include Takeda, Pfizer, Sanofi, BioMarin, Merck, Actelion Pharmaceuticals and Eli Lilly, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Lysosomal Storage Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lysosomal Storage Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Lysosomal Storage Disease Treatment Market Segment Percentages, by Type, 2021 (%)
Enzyme Replacement Therapy
Stem Cell Transplantation
Substrate Reduction Therapy
Others
Global Lysosomal Storage Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Lysosomal Storage Disease Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Stem Transplant Centers
Research Organizations
Others
Global Lysosomal Storage Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Lysosomal Storage Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Lysosomal Storage Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Lysosomal Storage Disease Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Takeda
Pfizer
Sanofi
BioMarin
Merck
Actelion Pharmaceuticals
Eli Lilly